Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DULR78
|
|||
| Drug Name |
PB-119
|
|||
| Synonyms |
PEGylated exenatide
Click to Show/Hide
|
|||
| Indication | Type 2 diabetes [ICD-11: 5A11; ICD-10: E08-E13] | Phase 3 | [1] | |
| Company |
PegBio
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Agonist | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Insulin secretion | ||||
| Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
| G alpha (s) signalling events | ||||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04504396) A Multicenter, Randomized, Double-blinded, Placebo-controlled Trial Comparing the Efficacy and Safety of PB-119 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Alone. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of PegBio | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.